CYT-503 / Cytovia Therap, National Cancer Institute, CytoLynx Therap - LARVOL DELTA

Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to Fight Cancer (PRNewswire) - "Cytovia plans to focus on multiple milestones, including: Filing the first two INDs for Flex-NK™ CYT-303 and iNK CYT-100; Initiating Phase I/II clinical trials to evaluate CYT-303 and CYT-100, alone and in combination, for the treatment of HCC; Obtaining and presenting initial clinical data for CYT-303 and CYT-100 in HCC; Filing INDs for CYT-150 and CYT-503 and initiating Phase I/II clinical trials."

Clinical data • IND • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors (GlobeNewswire) - "Cytovia Therapeutics...announced...that it has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited iPSC-derived NK cell technology to develop GPC3 CAR NK cell therapeutics....Cytovia has also signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. Under the CRADA, Cytovia will collaborate with Dr. Ho’s laboratory to develop and evaluate gene-edited iPSC-derived GPC3 CAR NK cells. Cytovia expects to file an initial new drug application (IND) for its GPC3 CAR NK cells in the first half of 2022."

IND • Licensing / partnership • Oncology